|SECURITIES AND EXCHANGE COMMISSION|
|Washington, DC 20549|
|CURRENT REPORT Pursuant|
|to Section 13 or 15(d) of the|
|Securities Exchange Act of 1934|
|Date of report (Date of earliest event reported): October 22, 2018|
Bionik Laboratories Corp.
|(State or Other Jurisdiction of Incorporation or Organization)||(Commission File Number)||(IRS Employer Identification No.)|
483 Bay Street, N105
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s Telephone Number, Including Area Code: (416) 640-7887
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).|
|Emerging growth company ¨|
|If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On October 22, 2018, the Compensation Committee of the Board of Directors of Bionik Laboratories Corp. (the “Company”) ratified the vesting of 508,873 options (the “Vested Options”) previously granted to Dr. Eric Dusseux, the Company’s CEO and a director, pursuant to the following performance criteria:
|·||Work with investors to ensure conversion of convertible loans and raise an additional minimum $7 million from July 2017;|
|·||Establish a plan to uplist to a U.S. stock exchange and associated IR plan;|
|·||Release new version of InMotion Arm before end of 2017;|
|·||Secure production capacity and quality by outsourcing production of InMotion arm to an established partner before March 2018; and|
|·||Engage Curexo into an exclusive distribution agreement before June 2018.|
The Vested Options have an exercise price based on the $0.161 closing price of the Company’s common stock on the September 1, 2017 date of grant, and expire on September 1, 2027.
On October 24, 2018, the Company issued a press release announcing that it has entered into a purchase order with Clinique Les Trois Soleils in Boissise-le-Roi, France for the Company’s InMotion Arm™ robot, and that the Company recently received a “CE marking” from the European Commission.
A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|Item 9.01||Financial Statements and Exhibits.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: October 24, 2018
|BIONIK LABORATORIES CORP.|
|By:||/s/ Leslie Markow|
|Title:||Chief Financial Officer|